

Vik Khullar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4681975/publications.pdf>

Version: 2024-02-01

44
papers

1,629
citations

471061

17
h-index

288905

40
g-index

47
all docs

47
docs citations

47
times ranked

1307
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and Tolerability of Mirabegron, a β ³ -Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European–Australian Phase 3 Trial. <i>European Urology</i> , 2013, 63, 283-295.	0.9	370
2	The Effects of Antimuscarinic Treatments in Overactive Bladder: A Systematic Review and Meta-Analysis. <i>European Urology</i> , 2005, 48, 5-26.	0.9	233
3	Fesoterodine Dose Response in Subjects With Overactive Bladder Syndrome. <i>Urology</i> , 2008, 71, 839-843.	0.5	96
4	Do overactive bladder symptoms improve after repair of anterior vaginal wall prolapse?. <i>International Urogynecology Journal</i> , 2007, 18, 1439-1443.	0.7	86
5	The effects of antimuscarinics on health-related quality of life in overactive bladder: A systematic review and meta-analysis. <i>Urology</i> , 2006, 68, 38-48.	0.5	85
6	The effect of mode of delivery on pelvic floor functional anatomy. <i>International Urogynecology Journal</i> , 2008, 19, 407-416.	0.7	80
7	The relationship between BMI and urinary incontinence subgroups: Results from EpiLUTS. <i>Neurourology and Urodynamics</i> , 2014, 33, 392-399.	0.8	72
8	Current controversies in urinary tract infections: ICI–ERS 2017. <i>Neurourology and Urodynamics</i> , 2018, 37, S86-S92.	0.8	65
9	Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial. <i>BMC Urology</i> , 2013, 13, 45.	0.6	56
10	Efficacy of the β ³ -adrenoceptor Agonist Mirabegron for the Treatment of Overactive Bladder by Severity of Incontinence at Baseline: A Post Hoc Analysis of Pooled Data from Three Randomised Phase 3 Trials. <i>European Urology</i> , 2015, 67, 11-14.	0.9	47
11	Reproducibility and reliability of pressure flow parameters in women. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2003, 110, 774-776.	1.1	45
12	Posterior tibial nerve stimulation for overactive bladder—techniques and efficacy. <i>International Urogynecology Journal</i> , 2020, 31, 865-870.	0.7	41
13	Pressure flow study: A useful diagnostic test of female lower urinary tract symptoms. <i>Neurourology and Urodynamics</i> , 2004, 23, 104-108.	0.8	29
14	The use of laser in urogynaecology. <i>International Urogynecology Journal</i> , 2019, 30, 683-692.	0.7	27
15	?Unblinding? in randomized controlled drug trials for urinary incontinence: Implications for assessing outcomes when adverse effects are evident. <i>Neurourology and Urodynamics</i> , 2005, 24, 13-20.	0.8	24
16	Patient–reported outcomes with the β ³ -adrenoceptor agonist mirabegron in a phase III trial in patients with overactive bladder. <i>Neurourology and Urodynamics</i> , 2016, 35, 987-994.	0.8	23
17	Systematic Review of Combination Drug Therapy for Non-neurogenic Lower Urinary Tract Symptoms. <i>European Urology</i> , 2019, 75, 129-168.	0.9	19
18	Intraobserver and interobserver reliability of the three-dimensional ultrasound imaging of female urethral sphincter using a translabial technique. <i>International Urogynecology Journal</i> , 2012, 23, 1063-1068.	0.7	18

#	ARTICLE	IF	CITATIONS
19	Patient-reported outcomes and different approaches to urinary parameters in overactive bladder: what should we measure?. International Urogynecology Journal, 2012, 23, 179-192.	0.7	17
20	Bladder wall thickness in women with symptoms of overactive bladder and detrusor overactivity: Results from the randomised, placebo-controlled shrink study. Neurourology and Urodynamics, 2016, 35, 819-825.	0.8	16
21	Racial differences in female urethral morphology and levator hiatal dimensions: An ultrasound study. Neurourology and Urodynamics, 2012, 31, 502-507.	0.8	15
22	Interstitial cystitis/bladder pain syndrome and recurrent urinary tract infection and the potential role of the urinary microbiome. Post Reproductive Health, 2020, 26, 87-90.	0.3	13
23	Clinical value of a patient-reported goal attainment measure: the global development of self-assessment goal achievement (SAGA) questionnaire for patients with lower urinary tract symptoms. Neurourology and Urodynamics, 2014, 33, 90-94.	0.8	12
24	Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people >65 years of age: A post hoc analysis of data from the SOFIA study. Neurourology and Urodynamics, 2015, 34, 438-443.	0.8	12
25	Midurethral slings for treatment of stress urinary incontinence review. Neurourology and Urodynamics, 2019, 38, S70-S75.	0.8	12
26	Abnormal vaginal microbiome associated with vaginal mesh complications. Neurourology and Urodynamics, 2019, 38, 2255-2263.	0.8	11
27	The role of bladder instillation in the treatment of bladder pain syndrome: Is intravesical treatment an effective option for patients with bladder pain as well as LUTS?. International Urogynecology Journal, 2020, 31, 1387-1392.	0.7	11
28	Effects of drug cessation after flexible-dose fesoterodine in patients with overactive bladder. BJU International, 2013, 112, 820-829.	1.3	10
29	Personal goals and expectations of OAB patients in the UK. Neurourology and Urodynamics, 2017, 36, 1194-1200.	0.8	9
30	European content validation of the Self-Assessment Goal Achievement (SAGA) questionnaire in patients with overactive bladder. International Urogynecology Journal, 2013, 24, 1529-1536.	0.7	8
31	Urodynamics are necessary for patients with asymptomatic pelvic organ prolapse. Neurourology and Urodynamics, 2018, 37, 2841-2846.	0.8	8
32	How can we improve the diagnosis and management of bladder pain syndrome? Part 2: ICIERS 2018. Neurourology and Urodynamics, 2019, 38, S71-S81.	0.8	8
33	Tolterodine ER reduced increased bladder wall thickness in women with overactive bladder. A randomized, placebo-controlled, double-blind, parallel group study. Neurourology and Urodynamics, 2018, 37, 237-243.	0.8	7
34	Recommendations and future research initiative to optimize bladder management in pregnancy and childbirth International Consultation on Incontinence - Research society 2018. Neurourology and Urodynamics, 2019, 38, S104-S110.	0.8	7
35	Time-to-effect with darifenacin in overactive bladder: a pooled analysis. International Urogynecology Journal, 2011, 22, 1573-1580.	0.7	6
36	Validation study of ultrasound bladder wall thickness measurements. International Urogynecology Journal, 2019, 30, 1575-1580.	0.7	6

#	ARTICLE	IF	CITATIONS
37	Under what circumstances should stress incontinence surgery be performed at the same time as prolapse surgery? ICIâ€RS 2015. Neurourology and Urodynamics, 2017, 36, 909-914.	0.8	5
38	Emerging drugs for overactive bladder. Expert Opinion on Emerging Drugs, 2015, 20, 613-624.	1.0	4
39	How can we improve the diagnosis and management of bladder pain syndrome? Part 1: ICIâ€RS 2018. Neurourology and Urodynamics, 2019, 38, S66-S70.	0.8	4
40	Does size matter? Perineometer and digital examination of a model levator hiatus. Neurourology and Urodynamics, 2020, 39, 1338-1344.	0.8	3
41	Does cystoscopy method affect the investigation of bladder pain syndrome/interstitial cystitis?. International Urogynecology Journal, 2021, 32, 1229-1235.	0.7	3
42	Female pelvic surgical devices and techniques need better evidenceâ€based medicine. Neurourology and Urodynamics, 2010, 29, 670-675.	0.8	2
43	Can we harness the placebo effect to improve care in lower urinary tract dysfunction? ICIâ€RS 2019. Neurourology and Urodynamics, 2020, 39, S80-S87.	0.8	2
44	Urogynaecology and Ehlersâ€Danlos syndrome. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2021, 187, 579-585.	0.7	2